Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer

NCT00252564 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT00252564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer
Lead sponsor
US Oncology Research
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
June 30, 2009
Enrollment
247 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer